Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $26.0552W HIGH $42.68
Volume
548.73 K
Value Traded
26.44 M
Short % Float
11.03%
-3.48%Week
-5.97%1 Month
-2.51%3 Month
+18.23%6 Month
+43%5 Year
+107.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.17 B
EPS (TTM)
-1.81
P/E Ratio
-
Ent. Value
1.93 B
Total Shares
87.87 M
Float Shares
90.08 M
Insiders
6.64%
Institutions
101.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IDYA Catalyst Timeline
Dated clinical, regulatory and corporate events for IDEAYA Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for IDEAYA Biosciences, Inc.
415Total events
28Upcoming
79Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Dr. Michael White promoted from Chief Scientific Officer to President, Research and Development
▲First Patient DosedDarovasertibFiledTrial
First patient dosed in OptimUM-11 Phase 3 adjuvant uveal melanoma trial
primary uveal melanoma (adjuvant therapy)source ↗
●Trial InitiationDarovasertibFiledTrial
OptimUM-11 global Phase 3 registrational trial of darovasertib + crizotinib initiated
primary uveal melanoma (adjuvant therapy)source ↗
●NDA SubmissionDarovasertibFiledRegulatory Filing
NDA submission initiated for darovasertib + crizotinib in first line mUM
first line metastatic uveal melanoma (mUM)source ↗
◆Oral PresentationIDE849Presentation
Clinical data updates for IDE849 in 100 ES-SCLC and NEC patients at ESMO 2026
ES-SCLC and NECsource ↗
▲Type C MeetingIDE849FDA Meeting
Successful FDA Type C meeting for IDE849 Phase 3 registrational trial design
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Partnership / LicenseIDE892Corporate
IDEAYA enters clinical collaboration with Genentech to evaluate IDE892 in combination with GDC-7035
MTAP-deleted KRAS G12D-mutant pancreatic ductal adenocarcinomasource ↗
▲Primary Endpoint MetDarovasertibFiledClinical Data
OptimUM-02 met primary endpoint of PFS
metastatic uveal melanomasource ↗
▲Enrollment CompleteDarovasertibFiledTrial
Enrollment completed for approximately 100 HLA*A2:01-positive mUM patients
metastatic uveal melanomasource ↗
●Trial InitiationDarovasertibFiledTrial
Global Phase 3 registrational trial OptimUM-11 initiated
adjuvant primary uveal melanomasource ↗
●Type C MeetingDarovasertibFiledFDA Meeting
Type C meeting with FDA completed earlier this year
adjuvant primary uveal melanomasource ↗
▲Trial InitiationIDE892Trial
Monotherapy expansion initiated in Phase 1/2 trial
MTAP-deleted solid tumorssource ↗
▲Enrollment CompleteIDE892Trial
Part 2 monotherapy expansion initiated for IDE892
MTAP-deleted solid tumors (NSCLC and PDAC)source ↗
▲Trial InitiationIDE892Trial
IDE892 Part 2 monotherapy expansion initiated
MTAP-deleted solid tumors (NSCLC, PDAC)source ↗
◆Topline ReadoutIDE849Clinical Data
First clinical data from global Phase 1/2 trial expected H2 2026
SCLC and NECsource ↗
▲First Patient DosedIDE892Trial
First patient enrolled in Phase 1 combination trial of IDE892 + IDE397 in MTAP-deleted solid tumors
MTAP-deleted solid tumors (NSCLC, pancreatic cancer)source ↗
▼Equity OfferingCorporate
Closing of underwritten public offering of common stock and pre-funded warrants, including full exercise of underwriters' option, raising approximately $345.0 million in gross proceeds
▼Equity OfferingCorporate
Proposed public offering of common stock and pre-funded warrants up to $300 million
▲Partnership / LicenseCorporate
Clinical collaboration with Roche to evaluate IDE892 + RG6505 in MTAP-deleted RAS-mutant PDAC
▲Trial InitiationIDE892Trial
Phase 1 dose escalation trial of IDE892 in MTAP-deleted solid tumors ongoing
MTAP-deleted solid tumorssource ↗
▲Late-BreakerDarovasertibFiledPresentation
Late-breaking oral presentation of complete data from primary analysis of OptimUM-02 at ASCO 2026
first line HLA*A2:01 negative metastatic uveal melanomasource ↗
▲Topline ReadoutDarovasertibFiledClinical Data
Primary PFS results from OptimUM-02 trial: darovasertib + crizotinib vs investigator's choice in first-line HLA-A2 negative metastatic uveal melanoma
HLA-A2 negative metastatic uveal melanomasource ↗
▲Primary Endpoint MetDarovasertibFiledClinical Data
Primary endpoint PFS met with statistical significance
HLA-A2 negative metastatic uveal melanomasource ↗
◆Full ResultsDarovasertibFiledClinical Data
Primary results from OptimUM-02 presented at medical conference
HLA-A2 negative metastatic uveal melanomasource ↗
◆Oral PresentationDarovasertibFiledPresentation
Oral presentation of OptimUM-02 primary results
HLA-A2 negative metastatic uveal melanomasource ↗
◆Oral PresentationPresentation
Fireside chat at Bank of America Merrill Lynch Health Care Conference
◆Oral PresentationDarovasertibFiledPresentation
Darovasertib Phase 2/3 OptimUM-02 topline results investor and analyst webcast at Bank of America Merrill Lynch Health Care Conference
first-line HLA-A2*-negative metastatic uveal melanomasource ↗
◆Timing GuidanceDarovasertibFiledPresentation
Updated guidance for topline data release from Phase 2/3 OptimUM-02 trial
first-line HLA-A2*-negative metastatic uveal melanomasource ↗
●Rolling Submission InitiatedDarovasertibFiledRegulatory Filing
First pre-submission of NDA completed under RTOR
first line HLA*A2:01 negative metastatic uveal melanomasource ↗
●NDA SubmissionDarovasertibFiledRegulatory Filing
Initiate NDA submission under RTOR program for darovasertib combination
first-line HLA*A2-negative metastatic uveal melanomasource ↗
▲Partnership / LicenseIDE892Corporate
Clinical collaboration with Roche to evaluate IDE892 + RG6505
MTAP-deleted, RAS-mutant pancreatic cancersource ↗
▲Topline ReadoutDarovasertibFiledClinical Data
Positive topline data from OptimUM-02 trial of darovasertib + crizotinib in 1L HLA*A2-negative mUM
first-line HLA*A2-negative metastatic uveal melanomasource ↗
▲Primary Endpoint MetDarovasertibFiledClinical Data
Darovasertib + crizotinib met primary endpoint of PFS in OptimUM-02 trial
first-line HLA-A*02:01-negative metastatic uveal melanomasource ↗
▲FDA Filing AcceptedDarovasertibFiledRegulatory Filing
FDA agreed to review NDA under RTOR program
first line HLA*A2:01 negative metastatic uveal melanomasource ↗
▲First Patient DosedIDE849Trial
First patient dosed in Phase 1 combination study of IDE849 and IDE161
DLL3 upregulated solid tumors (SCLC, NETs, NECs, melanoma)source ↗
▲Trial InitiationIDE849Trial
Phase 1 monotherapy trial for IDE849 initiated
DLL3 upregulated solid tumors (SCLC, NETs, NECs, melanoma)source ↗
●Enrollment UpdateIDE849Trial
Enrolling patients in IDE849 expansion cohort at 2.4 mg/kg Q3W
DLL3 upregulated solid tumors (SCLC, NETs, NECs, melanoma)source ↗
▲Primary Endpoint MetIDE849Clinical Data
Partial responses observed in SCLC patients pre-treated with tarlatamab
SCLCsource ↗
▲Milestone PaymentIDE034Corporate
$5 million milestone payment to Biocytogen triggered by first patient dosing
▲Topline ReadoutDarovasertibFiledClinical Data
Positive topline results from OptimUM-02 registrational trial
first-line HLA*A2-negative metastatic uveal melanomasource ↗
Past FDA Catalysts and PDUFA Decisions
How IDYA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | darovasertib combination | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$1.0B
Pipeline Value
Overvalued
Valuation Signal
7
Drugs Scored
0.3x
rNPV / MCap
Top 14%
Small Cap(rank 93 of 658)
Percentile Rank
IDEAYA Biosciences, Inc. carries a moderate pipeline score (53/100), with $1.6B risk-adjusted pipeline value, led by IDE892 in NSCLC Adenocarcinoma (Phase 1), across $50B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IDE892 Small moleculeNCT07277413 | NSCLC Adenocarcinoma | Phase 1 | RECRUITING | 260 | Apr 30, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every IDYA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| darovasertib BreakthroughFast TrackOrphan | HLA*A2:01 negative metastatic uveal melanoma | Phase 2/3 | 2026-06-02 | 313 patients, significant improvements in response rates and progression-free survivalRead More | IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCORead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hata Yujiro SDirector, Officer (President and CEO) | Option | 26,338 717,033 held | $4.31 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IDYA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.9 % (12.5 %) | 186.72 M | 5.01 M | 26.95% ( 1.06 M) |
IDYA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IDYA ranks across every disease it competes in
Competitive Position is a premium feature
See how IDYA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIDYA News
IDYAIDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
IDEAYA Biosciences has promoted Dr. Michael White to President of Research and Development, effective September 28, 2026. Dr. White, previously Chief Scientific Officer, has been instrumental in advancing the company's oncology pipeline. His leadership is expected to enhance IDEAYA's efforts in developing targeted therapies for various cancers, aiming to address significant unmet medical needs.
Read more →IDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced the granting of 94,000 stock options to three new employees as part of its 2023 Employment Inducement Incentive Award Plan. This move is compliant with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the company. The options have a 10-year term and will vest over four years, contingent on continued employment.
Read more →IDYAIDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
IDEAYA Biosciences and Servier have announced the dosing of the first patient in the OptimUM-11 Phase 3 trial. This study evaluates the combination of darovasertib and crizotinib as an adjuvant therapy for patients with primary uveal melanoma at risk of metastasis. The trial aims to establish a new treatment option in a setting with significant unmet needs.
Read more →IDYAIDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences has announced its upcoming Investor R&D Day in London on November 16, 2026, where it will discuss its development strategies for pancreatic cancer. The company will also participate in several investor conferences in September 2026, featuring key management discussions. A live audio webcast will be available for those unable to attend in person.
Read more →IDYAIDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
IDEAYA Biosciences announced a successful FDA Type C meeting regarding the Phase 3 registrational trial design for IDE849, a DLL3-targeting ADC in extensive stage small cell lung cancer (ES-SCLC). The company aims to begin the trial by the end of 2026, with a focus on overall response rate and median overall survival as primary endpoints. The study will enroll approximately 400 patients and evaluate various dose levels.
Read more →IDYAIDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA Biosciences has announced a clinical collaboration with Genentech to evaluate IDE892, a potential best-in-class PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor RG6620. This study targets patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma. Genentech will sponsor the trial, and both companies will retain commercial rights to their respective compounds.
Read more →IDYAIDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences reported positive results from its OptimUM-02 trial for darovasertib in metastatic uveal melanoma, with plans for a new drug application filing. The company also announced upcoming data presentations at ESMO and a clinical collaboration with Roche for IDE892 in pancreatic cancer. Despite a strong cash position of $1.24 billion, the company reported an increased net loss for the quarter.
Read more →IDYAIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences has initiated the Part 2 monotherapy expansion of IDE892 in its Phase 1/2 trial for MTAP-deleted pancreatic and lung cancers. The drug exhibits a promising profile with selective binding properties and has achieved target exposures. The ongoing dose escalation has not yet reached the maximum tolerated dose, indicating further potential for efficacy.
Read more →IDYAIDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
IDEAYA Biosciences announced three abstract presentations at the 2026 ESMO meeting, highlighting updates from its clinical pipeline. The presentations will cover ongoing trials of darovasertib in uveal melanoma and IDE849 in small cell lung carcinoma. The company aims to demonstrate the potential of these therapies as new treatment options.
Read more →IDYAIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
IDEAYA Biosciences has elected Yujiro S. Hata as Chairman of the Board. Hata, who is also the President and CEO, has been instrumental in the company's evolution into a leading precision medicine oncology firm. The company is focused on developing breakthrough therapies for cancer, addressing significant unmet medical needs.
Read more →IDYAIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE892, a promising PRMT5 inhibitor, in combination with IDE397 for treating MTAP-deleted pancreatic and lung cancers. The trial aims to address the significant unmet need for effective therapies in these cancer types, where MTAP deletion is prevalent. Preclinical results indicate strong anti-tumor activity, supporting the rationale for this combination therapy.
Read more →IDYAIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
IDEAYA Biosciences has successfully closed its public offering of 7,222,225 shares at $27.00 each, raising approximately $345 million. The offering included a full exercise of the underwriters' option for an additional 1,666,669 shares. The company aims to advance its precision medicine oncology initiatives with these funds.
Read more →IDYA▼ -10.8%on this newsshared move
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
IDEAYA Biosciences has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $300 million. The offering includes 5,555,556 shares of common stock priced at $27.00 each and pre-funded warrants at $26.9999. The transaction is expected to close around June 10, 2026, subject to customary conditions.
Read more →IDYA▲ +11.3%on this newsshared move
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
IDEAYA Biosciences announced a proposed public offering of up to $300 million in common stock and pre-funded warrants. The offering is subject to market conditions, and underwriters have a 30-day option to purchase an additional $45 million. The company aims to leverage this capital for its precision oncology initiatives.
Read more →IDYAIDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA Biosciences has announced a clinical collaboration with Roche to evaluate the efficacy of IDE892, a PRMT5 inhibitor, in combination with Roche's RG6505 for treating MTAP-deleted RAS-mutant pancreatic cancer. The trial aims to address the high unmet need in this patient population. Both companies will retain commercial rights to their respective compounds.
Read more →IDYAIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
IDEAYA Biosciences and Servier presented complete data from the Phase 2/3 OptimUM-02 trial at ASCO 2026, showcasing the darovasertib combination's effectiveness in treating HLA*A2:01 negative metastatic uveal melanoma. The trial demonstrated significant improvements in response rates and progression-free survival compared to existing therapies. The FDA is reviewing the NDA for this combination under the Real-time Oncology Review program, which may expedite approval.
Read more →IDYAHLA, human leukocyte antigen. mOS, median overall survival. mPFS, median progression free survival. PKC, protein kinase C. 1. Khoja L, et al. J Clin Oncol. 2025;43(suppl) [abstract 9539]. 2. Rantala ES, et al. Melanoma R
The OptimUM-02 trial evaluated the first-line treatment of darovasertib plus crizotinib for patients with HLA-A*02:01 negative metastatic uveal melanoma. Results indicated a significant improvement in progression-free survival (PFS) compared to standard treatments, demonstrating a 58% reduction in the risk of disease progression or death. The combination therapy presents a potential new option for a patient population with historically limited treatment choices, given the absence of FDA-approved therapies for this subgroup.
Read more →About IDEAYA Biosciences, Inc.
Headquarters5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next IDYA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime